NN 7128

Drug Profile

NN 7128

Alternative Names: GlycoPEGylated Factor VIIa - Novo Nordisk; LA-rFVIIa - Novo Nordisk; N7-GP; NN7128; NNC 0128-0000-2011; NNC 0128-0000-2021; rFVIIa long-acting analogue - Novo Nordisk

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Blood coagulation factors; Recombinant proteins; Serine endopeptidases
  • Mechanism of Action Factor VIIa stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haemophilia

Most Recent Events

  • 26 Jan 2011 Novo Nordisk initiates a phase I trial for Haemophilia in the UK (NCT01272206)
  • 03 Jun 2008 Adverse events data from a phase I trial in Haemophilia released by Novo Nordisk
  • 03 Jun 2008 Novo Nordisk completes an initial phase I trial in Haemophilia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top